JP2002532470A - パロキセチンマレイン酸塩の製法 - Google Patents

パロキセチンマレイン酸塩の製法

Info

Publication number: JP2002532470A
Authority: JP; Japan
Prior art keywords: paroxetine; solvent; maleate; methylenedioxyphenoxymethyl; fluorophenyl
Prior art date: 1998-12-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2000588135A

Other languages

English (en)

Japanese (ja)

Inventor

デイビッド・アラン・ジョーンズ

Original Assignee

スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-11

Filing date

1999-12-10

Publication date

2002-10-02

1999-12-10 Application filed by スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー filed Critical スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー

2002-10-02 Publication of JP2002532470A publication Critical patent/JP2002532470A/ja

Status Pending legal-status Critical Current

Links

AEIUZSKXSWGSRU-QXGDPHCHSA-N paroxetine maleate Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AEIUZSKXSWGSRU-QXGDPHCHSA-N 0.000 title claims abstract description 29
238000002360 preparation method Methods 0.000 title description 4
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims abstract description 24
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims abstract description 22
229960002296 paroxetine Drugs 0.000 claims abstract description 22
239000002904 solvent Substances 0.000 claims abstract description 20
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims abstract description 18
RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims abstract description 17
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 17
239000012458 free base Substances 0.000 claims abstract description 13
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 13
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims abstract description 12
239000011976 maleic acid Substances 0.000 claims abstract description 12
150000002576 ketones Chemical class 0.000 claims abstract description 8
239000004215 Carbon black (E152) Substances 0.000 claims abstract 3
229930195733 hydrocarbon Natural products 0.000 claims abstract 3
JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 claims abstract 2
150000002430 hydrocarbons Chemical class 0.000 claims abstract 2
238000000034 method Methods 0.000 claims description 20
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
150000001875 compounds Chemical class 0.000 claims description 12
238000002425 crystallisation Methods 0.000 claims description 10
230000008025 crystallization Effects 0.000 claims description 10
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 6
238000001914 filtration Methods 0.000 claims description 5
230000002265 prevention Effects 0.000 claims description 5
150000002688 maleic acid derivatives Chemical class 0.000 claims description 4
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 3
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
230000000069 prophylactic effect Effects 0.000 claims description 2
238000001816 cooling Methods 0.000 claims 1
150000002148 esters Chemical class 0.000 claims 1
238000010438 heat treatment Methods 0.000 claims 1
125000001183 hydrocarbyl group Chemical group 0.000 claims 1
-1 or an alkanol Substances 0.000 abstract description 2
239000007810 chemical reaction solvent Substances 0.000 abstract 1
238000001953 recrystallisation Methods 0.000 abstract 1
150000003839 salts Chemical class 0.000 description 13
239000012535 impurity Substances 0.000 description 8
239000000203 mixture Substances 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
239000012453 solvate Substances 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
239000003814 drug Substances 0.000 description 3
208000019906 panic disease Diseases 0.000 description 3
239000000047 product Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
206010036618 Premenstrual syndrome Diseases 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
239000002585 base Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
208000007848 Alcoholism Diseases 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000000648 anti-parkinson Effects 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
208000024732 dysthymic disease Diseases 0.000 description 1
238000011049 filling Methods 0.000 description 1
125000001207 fluorophenyl group Chemical group 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000008187 granular material Substances 0.000 description 1
208000024963 hair loss Diseases 0.000 description 1
230000003676 hair loss Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
239000012265 solid product Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
201000009032 substance abuse Diseases 0.000 description 1
231100000736 substance abuse Toxicity 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

JP2000588135A 1998-12-11 1999-12-10 パロキセチンマレイン酸塩の製法 Pending JP2002532470A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9827387.3A GB9827387D0 (en)	1998-12-11	1998-12-11	Novel process
GB9827387.3		1998-12-11
PCT/GB1999/004175 WO2000035873A1 (fr)	1998-12-11	1999-12-10	Procede de preparation de maleate de paroxetine

Publications (1)

Publication Number	Publication Date
JP2002532470A true JP2002532470A (ja)	2002-10-02

Family

ID=10844113

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2000588135A Pending JP2002532470A (ja)	1998-12-11	1999-12-10	パロキセチンマレイン酸塩の製法

Country Status (5)

Country	Link
EP (1)	EP1137636A1 (fr)
JP (1)	JP2002532470A (fr)
AU (1)	AU1987400A (fr)
GB (1)	GB9827387D0 (fr)
WO (1)	WO2000035873A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002053540A1 (fr)	2000-12-29	2002-07-11	Pfizer Limited	Derive aspartate de l'amlodipine utilise comme antagoniste des canaux calciques
EP1309557B9 (fr)	2000-12-29	2006-11-15	Pfizer Limited	Amlodipine hemimaleate
CA2433193C (fr)	2000-12-29	2006-01-31	Pfizer Limited	Derive d'amide d'amlodipine
US7335380B2 (en)	2000-12-29	2008-02-26	Synthon Ip Inc.	Amlodipine free base
AT5874U1 (de)	2000-12-29	2003-01-27	Bioorg Bv	Pharmazeutische zubereitungen enthaltend amlodipinmaleat
EP1309556B1 (fr)	2000-12-29	2004-11-24	Pfizer Limited	Fumarate d'amlodipine
WO2002054062A2 (fr)	2000-12-29	2002-07-11	Pfizer Limited	Standards de reference destines a la determination de la purete ou de la stabilite de maleate d'amlodipine et procedes correspondants
PL362660A1 (en)	2000-12-29	2004-11-02	Pfizer Limited	Process for making amlodipine maleate
MXPA03005882A (es)	2000-12-29	2005-04-19	Pfizer Ltd	Derivado amida de amlodipina.
US6653481B2 (en)	2000-12-29	2003-11-25	Synthon Bv	Process for making amlodipine
CN110294692B (zh) *	2019-07-26	2020-09-01	河北兰升生物科技有限公司	一种改进的顺式-对位取代的环己基氨基腈马来酸盐的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1422263A (en) *	1973-01-30	1976-01-21	Ferrosan As	4-phenyl-piperidine compounds
EP0223403B1 (fr) *	1985-10-25	1993-08-04	Beecham Group Plc	Dérivé de pipéridine, sa préparation et son utilisation comme médicament
EA200001050A1 (ru) *	1998-04-09	2001-04-23	Смитклайн Бичам Плс	Малеат пароксетина
ES2138937B1 (es) *	1998-07-07	2000-10-01	Medichem Sa	Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.

1998
- 1998-12-11 GB GBGB9827387.3A patent/GB9827387D0/en not_active Ceased
1999
- 1999-12-10 EP EP99963631A patent/EP1137636A1/fr not_active Withdrawn
- 1999-12-10 JP JP2000588135A patent/JP2002532470A/ja active Pending
- 1999-12-10 WO PCT/GB1999/004175 patent/WO2000035873A1/fr not_active Ceased
- 1999-12-10 AU AU19874/00A patent/AU1987400A/en not_active Abandoned

Also Published As

Publication number	Publication date
GB9827387D0 (en)	1999-02-03
WO2000035873A1 (fr)	2000-06-22
EP1137636A1 (fr)	2001-10-04
AU1987400A (en)	2000-07-03

Publication	Publication Date	Title
JP2001522780A (ja)	2001-11-20	オメプラゾールの新規な結晶形
JP2002519422A (ja)	2002-07-02	パロキセチンメタンスルホネート
JP2007302658A (ja)	2007-11-22	イマチニブメシレートの多形フォーム及び新規結晶フォーム及び非晶フォーム並びにフォームαの調製方法
JP5086069B2 (ja)	2012-11-28	重硫酸アタザナビルおよび新規形態の製造方法
JP2001519346A (ja)	2001-10-23	抗真菌性結晶性多形物
JP2014530805A (ja)	2014-11-20	アジルサルタンの結晶形並びにその製造及び使用
EP0579681B1 (fr)	1999-06-02	Monohydrate d'hydrochlorure de tiagabine cristalline, sa preparation et son utilisation
JP2002532470A (ja)	2002-10-02	パロキセチンマレイン酸塩の製法
JP2015508090A (ja)	2015-03-16	固体形態のダビガトランエテキシレートメシレート及びその調製方法
TWI445697B (zh)	2014-07-21	塔適那偉（ａｔａｚａｎａｖｉｒ）硫酸氫鹽之製法及其新穎的形式
JPH0848685A (ja)	1996-02-20	テラゾシンモノヒドロクロリド及びその製造法並びに該化合物を製造するための中間体
JP2004504390A (ja)	2004-02-12	（ｒ）−ｎ−［５−メチル−８−（４−メチルピペラジン−１−イル）−１，２，３，４−テトラヒドロ−２−ナフチル］−４−モルホリノベンズアミドの新規な形態
JP2002532494A (ja)	2002-10-02	パロキセチンの誘導体
EP0703915B1 (fr)	2000-09-27	Xamoneline tartrate
JP2002505254A (ja)	2002-02-19	パロキセチン塩
JP2002511466A (ja)	2002-04-16	マレイン酸パロキセチン
RU2192416C2 (ru)	2002-11-10	Способ кристаллизации гидрохлорида 1-[2-(2-нафтил)этил]-4-(3-трифторметилфенил)-1,2,3,6-тетрагидропиридина, полученные кристаллические формы и фармацевтическая композиция
EP2072510A1 (fr)	2009-06-24	Forme cristalline d'azélastine
JP2002531451A (ja)	2002-09-24	パロキセチン塩酸塩の製法
JP2002531453A (ja)	2002-09-24	パロキセチン塩酸塩アセトン溶媒和物の製法
JP2002531452A (ja)	2002-09-24	混合パロキセチンプロパン−２−オール溶媒和物
JP3001975B2 (ja)	2000-01-24	結晶性チアガビン塩酸塩−水和物、その製造方法および用途
WO2000078752A1 (fr)	2000-12-28	Procede de production de chlorhydrate de paroxetine
JP2002533441A (ja)	2002-10-08	酢酸パロキセチンおよびそのアナログの製造法
JP2002531450A (ja)	2002-09-24	パロキセチン・塩酸塩の製造方法